Detection of minimal residual disease in childhood acute lymphoblastic leukemia: technology and clinical applications

被引:0
作者
Pawlowska, Anna B. [1 ]
机构
[1] City Hope Natl Med Ctr, 1500 Duarte Rd, Duarte, CA 91010 USA
来源
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY | 2005年 / 9卷 / 04期
关键词
review; pediatric acute lymphoblastic leukemia; minimal residual disease; flow cytometry; polymerase chain reaction;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
At the time of achieving clinical remission, patients with acute lymphoblastic leukemia (ALL) may harbor up to 1010 residual leukemic blasts. Detection of these cells is beyond the sensitivity level of classical cytomorphologic methods; they represent Minimal Residual Disease (MRD). Sensitive techniques developed for MRD detection can better define the leukemic burden and detect the residual blasts at the 0.1-0.0001% level. The most promising techniques for MRD monitoring are flow cytometric detection of aberrant immunophenotypes and polymerase chain reaction analysis of clonal antigen-receptor gene rearrangements. These techniques allow monitoring of MRD in almost all patients with pediatric ALL (up to 95%). In published clinical trials, MRD detection proved to be an excellent prognostic factor in the outcome of children with ALL. Evaluation of early treatment response allows for precise risk stratification that may lead to the tailoring of the treatment intensity and the reduction of long-term toxicities. Additionally, the detection of an increase in the MRD level enables one to anticipate an impending relapse. In this review, I discuss techniques used for MRD detection as well as the prognostic value of MRD monitoring during frontline treatment of childhood leukemia, during treatment of relapsed disease, and prior to bone marrow transplantation for ALL.
引用
收藏
页码:178 / 182
页数:5
相关论文
共 34 条
[1]   Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL [J].
Bader, P ;
Hancock, J ;
Kreyenberg, H ;
Goulden, NJ ;
Niethammer, D ;
Oakhill, A ;
Steward, CG ;
Handgretinger, R ;
Beck, JF ;
Klingebiel, T .
LEUKEMIA, 2002, 16 (09) :1668-1672
[2]   ANALYSIS OF IG AND T-CELL RECEPTOR GENES IN 40 CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIAS AT DIAGNOSIS AND SUBSEQUENT RELAPSE - IMPLICATIONS FOR THE DETECTION OF MINIMAL RESIDUAL DISEASE BY POLYMERASE CHAIN-REACTION ANALYSIS [J].
BEISHUIZEN, A ;
VERHOEVEN, MAJ ;
VANWERING, ER ;
HAHLEN, K ;
HOOIJKAAS, H ;
VANDONGEN, JJM .
BLOOD, 1994, 83 (08) :2238-2247
[3]   Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias:: a new molecular target for detection of minimal residual disease [J].
Beishuizen, A ;
de Bruijn, MAC ;
Pongers-Willemse, MJ ;
Verhoeven, MAJ ;
van Wering, ER ;
Hählen, K ;
Breit, TM ;
de Bruin-Versteeg, S ;
Hooijkaas, H ;
van Dongen, JJM .
LEUKEMIA, 1997, 11 (12) :2200-2207
[4]   Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study [J].
Borowitz, MJ ;
Pullen, DJ ;
Shuster, JJ ;
Viswanatha, D ;
Montgomery, K ;
Willman, CL ;
Camitta, B .
LEUKEMIA, 2003, 17 (08) :1566-1572
[5]  
BREIT TM, 1993, LEUKEMIA, V7, P2004
[6]   Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia [J].
Cavé, H ;
ten Bosch, JV ;
Suciu, S ;
Guidal, C ;
Waterkeyn, C ;
Otten, J ;
Bakkus, M ;
Thielemans, K ;
Grandchamp, B ;
Vilmer, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :591-598
[7]   Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI [J].
Chessells, JM ;
Harrison, G ;
Richards, SM ;
Gibson, BE ;
Bailey, CC ;
Hill, FGH ;
Hann, IM .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (02) :445-455
[8]   Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia [J].
Coustan-Smith, E ;
Sancho, J ;
Behm, FG ;
Hancock, ML ;
Razzouk, BI ;
Ribeiro, RC ;
Rivera, GK ;
Rubnitz, JE ;
Sandlund, JT ;
Pui, CH ;
Campana, D .
BLOOD, 2002, 100 (01) :52-58
[9]   Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia [J].
Coustan-Smith, E ;
Sancho, J ;
Hancock, ML ;
Boyett, JM ;
Behm, FG ;
Raimondi, SC ;
Sandlund, JT ;
Rivera, GK ;
Rubnitz, JE ;
Ribeiro, RC ;
Pui, CH ;
Campana, D .
BLOOD, 2000, 96 (08) :2691-2696
[10]   Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia [J].
Coustan-Smith, E ;
Behm, FG ;
Sanchez, J ;
Boyett, JM ;
Hancock, ML ;
Raimondi, SC ;
Rubnitz, JE ;
Rivera, GK ;
Sandlund, JT ;
Pui, CH ;
Campana, D .
LANCET, 1998, 351 (9102) :550-554